Can-Fite BioPharma Ltd. CANF
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Can-Fite BioPharma Ltd. (CANF) is a healthcare company listed in the US with a market value of about $4M. In the twelve months to June 30, 2026 it had revenue of $405000 and net income of -$10M, a net margin of -2358.8%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -12% a year, a 5-year average ROIC of -121%.
About Can-Fite BioPharma
Can-Fite BioPharma is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $789000 in 2017 to $405000 in 2025, a decline of about 8.0% a year. It was profitable in 1 of the last 10 years in our data. It spends 1653% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $405000 | $405000 | $674000 | $743000 | $810000 | $853000 | $763000 | $2M | $4M | $789000 | — |
| Net income | -$10M | -$10M | -$8M | -$8M | -$10M | -$13M | -$14M | -$13M | -$7M | -$6M | $8M |
| Free cash flow | -$10M | -$9M | -$8M | -$8M | -$11M | -$10M | -$12M | -$11M | -$4M | -$9M | -$9M |
| EPS (diluted) | $-3.15 | $-3.24 | $-2.60 | $-2.52 | $-3.36 | $-4.16 | $-4.76 | $-4.16 | $-2.17 | $-2.09 | $2.72 |
| Net margin | -2358.8% | -2426.7% | -1169.1% | -1027.5% | -1255.9% | -1478.9% | -1892.9% | -621.3% | -172.0% | -803.4% | — |
| ROIC | — | -138.8% | -115.9% | -103.0% | -175.9% | -69.9% | -181.9% | -376.9% | -141.9% | -190.2% | -115.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 1 analysts is $8.00, 463% above the current price; targets range from $8.00 to $8.00; the consensus rating is “none”; expected EPS is $-2.04 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Can-Fite BioPharma pay a dividend?
Not currently.
Is Can-Fite BioPharma a good stock to buy?
We do not give buy or sell advice. Can-Fite BioPharma scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.